Effects of pioglitazone and fenofibrate co-administration on bone biomechanics and histomorphometry in ovariectomized rats

[1]  S. Kliewer,et al.  Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ , 2012, Proceedings of the National Academy of Sciences.

[2]  S. Kliewer,et al.  Fibroblast Growth Factor-21 Regulates PPARγ Activity and the Antidiabetic Actions of Thiazolidinediones , 2012, Cell.

[3]  Susan Y. Smith,et al.  Combination treatment with pioglitazone and fenofibrate attenuates pioglitazone-mediated acceleration of bone loss in ovariectomized rats. , 2012, The Journal of endocrinology.

[4]  J. Reseland,et al.  The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats , 2011, BMC endocrine disorders.

[5]  B. Staels,et al.  Fibrates, Glitazones, and Peroxisome Proliferator–Activated Receptors , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[6]  F. Karpe,et al.  PPARδ in humans: genetic and pharmacological evidence for a significant metabolic function , 2009, Current opinion in lipidology.

[7]  S. Mudaliar,et al.  Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study , 2009, The Lancet.

[8]  M. Hanefeld,et al.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial , 2009, The Lancet.

[9]  N. Bishop,et al.  The Peroxisome Proliferator Activator Receptor Alpha/Delta Agonists Linoleic Acid and Bezafibrate Upregulate Osteoblast Differentiation and Induce Periosteal Bone Formation In Vivo , 2008, Calcified Tissue International.

[10]  C. Ankarberg-Lindgren,et al.  Twenty-four hours secretion pattern of serum estradiol in healthy prepubertal and pubertal boys as determined by a validated ultra-sensitive extraction RIA , 2008, BMC endocrine disorders.

[11]  A. Schwartz.  TZDs and Bone: A Review of the Recent Clinical Evidence , 2008, PPAR research.

[12]  A. Hermann,et al.  Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. , 2008, The Journal of clinical endocrinology and metabolism.

[13]  L. Suva,et al.  Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. , 2007, Endocrinology.

[14]  I. Reid,et al.  The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. , 2007, The Journal of clinical endocrinology and metabolism.

[15]  B. Zinman,et al.  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.

[16]  A. Schwartz.  Diabetes, TZDs, and Bone: A Review of the Clinical Evidence , 2006, PPAR research.

[17]  K. Seuwen,et al.  Enhanced Marrow Adipogenesis and Bone Resorption in Estrogen-Deprived Rats Treated with the PPARgamma Agonist BRL49653 (Rosiglitazone) , 2004, Calcified Tissue International.

[18]  S. Jackson,et al.  Peroxisome proliferator‐activated receptor activators modulate the osteoblastic maturation of MC3T3‐E1 preosteoblasts , 2000, FEBS letters.

[19]  N. Tajima,et al.  Effect of troglitazone on body fat distribution in type 2 diabetic patients. , 1999, Diabetes care.

[20]  M. Lean,et al.  Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. , 1999, Diabetes care.

[21]  B. Spiegelman.  PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.

[22]  C H Turner,et al.  Basic biomechanical measurements of bone: a tutorial. , 1993, Bone.

[23]  M. Drezner,et al.  Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee , 1987 .

[24]  L. Suva,et al.  Bone is a target for the antidiabetic compound rosiglitazone. , 2004, Endocrinology.

[25]  [Combination treatment]. , 1969, Ortopedia maxilar.